Stocks Health care NUVB
NYSE · Health careNuvation Bio Inc. (NUVB)
Nuvation Bio Inc. brought in $169.9M of revenue over the twelve months to June 30, 2026, up 1,083.6% from a year earlier. It posted a net loss of $149.8M. In fiscal 2025 capital spending exceeded operating cash flow by $181.4M. At June 30, 2026 it held $258.6M in cash against $242.6M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.
What Nuvation Bio Inc. does
Nuvation Bio Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker NUVB.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $62.9M | -$204.6M | -$0.60 | -$181.4M |
| 2024 | $7.9M | -$567.9M | -$2.11 | -$130.4M |
| 2023 | $0 | -$75.8M | -$0.35 | n/a |
| 2022 | n/a | -$104.2M | -$0.48 | n/a |
| 2021 | n/a | -$86.8M | -$0.44 | n/a |
| 2020 | n/a | -$41.7M | -$0.43 | n/a |
Latest SEC filings
What Nuvation Bio Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 6, 2026
- August 6, 2026Quarterly report 10-Q · period to June 30, 2026
- July 6, 2026New debt 8-K
- June 30, 2026
- June 29, 2026
- June 29, 2026Form 305B2 filing 305B2
- June 26, 2026
- June 25, 2026
- May 27, 2026
- May 4, 2026
Questions about NUVB
What does Nuvation Bio Inc. do?
Nuvation Bio Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NYSE under the ticker NUVB.
Is Nuvation Bio Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $149.8M on revenue of $169.9M.
How much revenue does Nuvation Bio Inc. make?
Over the twelve months to June 30, 2026 Nuvation Bio Inc. reported revenue of $169.9M. That is 1,083.6% more than a year earlier.
When did Nuvation Bio Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the insider trade from August 21, 2026.
Similar companies
Follow NUVB
Get an email when Nuvation Bio Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow NUVB: get an email when it filesWhere the numbers come from
Financial figures are the values Nuvation Bio Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.